A phase I study of daily everolimus plus low-dose weekly cisplatin for patients with advanced solid tumors

Cancer Chemotherapy and Pharmacology

Volumn 69, Issue 3, 2012, Pages 591-598

  Fury, Matthew G ^a   Sherman, Eric ^a   Haque, Sofia ^a   Korte, Susan ^a   Lisa, Donna ^a   Shen, Ronglai ^a   Wu, Nian ^a   Pfister, David ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Cisplatin; Everolimus; Phase I; Solid tumor

Indexed keywords

CISPLATIN; EVEROLIMUS;

ADENOID CYSTIC CARCINOMA; ADULT; AGED; ANOREXIA; AREA UNDER THE CURVE; ARTICLE; BASAL CELL CARCINOMA; BREAST CANCER; CARCINOID; CLINICAL ARTICLE; COLORECTAL CARCINOMA; CONSTIPATION; COUGHING; DIARRHEA; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG ERUPTION; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG SAFETY; DYSPNEA; ENDOMETRIUM CANCER; EPISTAXIS; ESTHESIONEUROBLASTOMA; ETHMOID SINUS CARCINOMA; FATIGUE; FEMALE; HEAD AND NECK CARCINOMA; HUMAN; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; HYPERKALEMIA; HYPERTRIGLYCERIDEMIA; HYPOMAGNESEMIA; HYPONATREMIA; LARYNX SQUAMOUS CELL CARCINOMA; LEUKOPENIA; LOW DRUG DOSE; LUNG NON SMALL CELL CANCER; LYMPHOCYTOPENIA; MALE; MAXIMUM PLASMA CONCENTRATION; MELANOMA; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; ONCOCYTOMA; OPEN STUDY; ORAL SQUAMOUS CELL CARCINOMA; OROPHARYNX SQUAMOUS CELL CARCINOMA; PARANASAL SINUS CARCINOMA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PULMONARY CARCINOID; SENSORY NEUROPATHY; SIDE EFFECT; SINONASAL ESTHESIONEUROBLASTOMA; SOLID TUMOR; SQUAMOUS CELL CARCINOMA; STOMATITIS; THROMBOCYTOPENIA; THYROID MEDULLARY CARCINOMA; THYROID PAPILLARY CARCINOMA; TIME TO MAXIMUM PLASMA CONCENTRATION; VEIN THROMBOSIS;

ADMINISTRATION, ORAL; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INJECTIONS, INTRAVENOUS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASMS; SIROLIMUS; TOR SERINE-THREONINE KINASES; TREATMENT OUTCOME;

EID: 84859751053     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-011-1734-5     Document Type: Article

References (40)

1. Bertino J, O'Connor OA (2000) Oncologic disorders. In: Caruthers SG (ed) Clinical pharmacology, 4th edn. McGraw-Hill, New York, pp 799-871
2. Ilson D (2004) Phase II trial of weekly irinotecan/cisplatin in advanced esophageal cancer. Oncology 18(Suppl 14):22-25
3. Jagasia MH, Langer CL, Johnson DH et al (2001) Weekly irinotecan and cisplatin in advanced non-small cell lung cancer: a multicenter phase II study. Clin Cancer Res 7:68-73 (Pubitemid 32110206)
4. Ando M, Kobayashi K, Yoshimura A et al (2004) Weekly administration of irinotecan (CPT-11) plus cisplatin for refractory or relapsed small cell lung cancer. Lung Cancer 44:121-127 (Pubitemid 38317268)
5. Lippe P, Tummarello D, Monterubbianesi MC et al (1999) Weekly gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase II study. Ann Oncol 10:217-221 (Pubitemid 29113183)
6. Burch PA, Mailliard JA, Hillman DW et al (2005) Phase II study of gemcitabine plus cisplatin in patients with metastatic breast cancer: a north central cancer treatment group trial. Am J Clin Oncol 28:195-200
7. Ferrigno D, Buccheri G (2005) Weekly chemotherapy with cisplatin and paclitaxel in inoperable non-small cell lung cancer: an extended phase II study. Anticancer Res 25:4685-4692 (Pubitemid 41729531)
8. Kim S-W, Suh C, Lee SD et al (2003) Weekly low dose paclitaxel and cisplatin as first-line chemotherapy for advanced non-small cell lung cancer. Lung Cancer 41:221-226 (Pubitemid 36842786)
9. Niho S, Ohe Y, Kakinuma R et al (2002) Phase II study of docetaxel and cisplatin administered as three consecutive weekly infusions for advanced non-small cell lung cancer. Lung Cancer 35:209-214 (Pubitemid 34136100)
10. Donadio M, Ardine M, Berruti A et al (2005) Weekly cisplatin plus capecitabine in metastatic breast cancer patients heavily pretreated with both anthracyclines and taxanes. Oncology 69:408-413 (Pubitemid 41797917)
11. Engelman JA (2009) Targeting PI3 K signalling in cancer: opportunities, challenges, and limitations. Nat Rev Cancer 9:550-562
12. Samuels Y, Wang Z, Bardelli A et al (2004) High frequency of mutations of PIK3CA gene in human cancers. Science 304:554 (Pubitemid 38541907)
13. Sansal I, Sellers WR (2004) The biology and clinical relevance of the PTEN tumor suppressor pathway. J Clin Oncol 22:2954-2963 (Pubitemid 41079915)
14. Guertin DA, Sabatini DM (2007) Defining the role of mTOR in cancer. Cancer Cell 12:9-22 (Pubitemid 47001784)
15. Motzer RJ, Escudier B, Oudard S et al (2008) Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III study. Lancet 372:449-456
16. Yao JC, Phan AT, Chang DZ et al (2008) Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediate-grade neuroendocrine tumors: results of a phase II study. J Clin Oncol 26:4311-4318
17. Yao JC, Lombard-Bohas C, Baudin E et al (2010) Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trial. J Clin Oncol 28:69-76
18. Shi Y, Frankel A, Radvanyi LG et al (1995) Rapamycin enhances apoptosis and increases sensitivity to cisplatin in vitro. Cancer Res 55:1982-1988
19. Beuvink I, Boulay A, Fumagalli S et al (2005) The mTOR inhibitor RAD001 sensitizes tumor cells to DNA-damage induced apoptosis though inhibition of p21 translation. Cell 120:747-759 (Pubitemid 40568794)
20. Mondesire WH, Jian W, Zhang H et al (2004) Targeting mammalian target of rapamycin synergistically enhances chemotherapy-induced cytotoxicity in breast cancer cells. Clin Cancer Res 10:7031-7042 (Pubitemid 39383055)
21. Aissat N, Le Tourneau C, Ghoul A et al (2008) Antiproliferative effects of rapamycin as a single agent and in combination with carboplatin and paclitaxel in head and neck cancer cell lines. Cancer Chemother Pharmacol 62:305-313 (Pubitemid 351692089)
22. Chu W, Wangpaichitr M, Feun L et al (2005) Overcoming cisplatin resistance by mTOR inhibitor in lung cancer. Molecular Cancer 4:25
23. Therasse P, Arbuck SG, Eisenhauer EA et al (2000) New guidelines to evaluate the response to treatment in solid tumors. European organization for research and treatment of cancer, national cancer institute of the United States, national cancer institute of Canada. J Natl Cancer Inst 92:205-216
24. Nashan B (2002) Review of the proliferation inhibitor everolimus. Expert Opin Investig Drugs 11:1845-1857
25. O'Donnell A, Faivre S, Burris HA et al (2008) Phase I pharmacokinetic and pharmacodynamic study of the oral mammalian target of rapamycin inhibitor everolimus in patients with advanced solid tumors. J Clin Oncol 26:1588-1595
26. Cloughesy TF, Yoshimoto K, Nghiemphu P et al (2008) Antitumor activity of rapamycin in a phase I trial for patients with recurrent PTEN-deficient glioblastoma. PLoS Med 5:e8
27. O'Reilly KE, Rojo F, She Q-B et al (2006) mTOR inhibition induces upstream recetor tyrosine kinase signaling and activates Akt. Cancer Res 66:1500-1508 (Pubitemid 43259931)
28. Courtney KD, Corcoran RB, Engelman JA (2010) The PI3 K pathway as drug target in human cancer. J Clin Oncol 28:1075-1083
29. Sessa C, Tosi D, Vigano L et al (2010) Phase Ib study of weekly mammalian target of rapamycin inhibitor ridaforolimus (AP23573; MK-8669) with weekly paclitaxel. Ann Oncol 21:1315-1322
30. Molinolo AA, Hewitt SM, Amornphimoltham P et al (2007) Dissecting the Akt/mammalian target of rapamycin signaling network: emerging results from the head and neck cancer tissue array initiative. Clin Cancer Res 13:4964-4973 (Pubitemid 47502060)
31. Raimondi AR, Molinolo A, Gutkind JS (2009) Rapamycin prevents early onset of carcinogenesis in an oral-specific K-ras and p53 two-hit carcinogenesis model. Cancer Res 69:4159-4166
32. Cooper JS, Pajak TF, Forastiere AA et al (2004) Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. New Engl J Med 350:1937-1944
33. Bernier J, Domenge C, Ozsahin M et al (2004) Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. New Engl J Med 350:1945-1952 (Pubitemid 38580197)
34. Bachaud J-M, Cohen-Jonathan E, Alzieu C et al (1996) Combined post-operative radiotherapy and weekly cisplatin infusion for locally advanced head and neck carcinoma: Wnal report of a randomized trial. Int J Radiat Oncol Biol Phys 36:999-1004 (Pubitemid 27014483)
35. Nathan C-AO, Franklin S, Abreo FW et al (1999) Analysis of surgical margins with the molecular marker eIF4E: a prognostic factor in patients with head and neck cancer. J Clin Oncol 17:2909-2914 (Pubitemid 29415252)
36. Nathan CO, Amirghahari N, Abreo F et al (2004) Overexpressed eIF4E is functionally active in surgical margins of head and neck cancer patients via activation of the Akt/mammalian target of rapamycin pathway. Clin Cancer Res 10:5820-5827 (Pubitemid 39180961)
37. Ekshyyan O, Rong Y, Rong X et al (2009) Comparison of radiosensitizing effects of the mammalian target of rapamycin inhibitor CCI-779 to cisplatin in experimental models of head and neck squamous cell carcinoma. Mol Cancer Ther 8:2255-2265
38. Manegold PC, Paringer C, Kulka U et al (2008) Antiangiogenic therapy with mammalian target of rapamycin inhibitor RAD001 (everolimus) increases radiosensitivity in solid cancer. Clin Cancer Res 14:892-900 (Pubitemid 351231174)
39. Fury MG. Radiation therapy (IMRT) + everolimus + cisplatin for patients with head and neck cancer. http://www.clinicaltrials.gov NCT00858663
40. Fury MG RAD001 (everolimus) + docetaxel + cisplatin as induction chemotherapy in patients with local-regional advanced head and neck squamous cell carcinoma (HNSCC). http://www.clinicaltrials.gov NCT00935961